Osmetech Raises $8.6M Through Private Placement | GenomeWeb

NEW YORK (GenomeWeb News) – British molecular diagnostics firm Osmetech has raised £5.2 million ($8.6 million) through a private placement of around 262 million new ordinary shares at a price of 2p each.

The new shares represent nearly 30 percent of the firm's now existing issued share capital. The placement was made last week.

Among the investors in the placement are the Efficacy Biotech Master Fund Ltd. and its affiliates, Gartmore and Schroder, the firm's principal shareholders, and certain new investors in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.